Impact on Research
Lymphoma Consortia, Initiatives and Scientific Workshops
The Lymphoma Research Foundation (LRF) seeks to eradicate this disease by supporting innovative research and the development of new and improved treatments for lymphoma. Direct investment in cutting-edge science is the primary way LRF advances its mission. Facilitating collaboration and partnerships among academic scientists, clinicians, government, and regulatory agencies, and patients is also a critical component of this work.
Through its global lymphoma consortia, research initiatives, and scientific workshops, LRF mobilizes the research community to overcome systemic challenges and speed the progress new treatments are developed.
Adolescent and Young Adult Lymphoma Consortium and Initiative
In 2014, LRF launched a multi-faceted adolescent and young adult (AYA) lymphoma initiative with its founding partner, The Paul Foundation, to assist young lymphoma patients in addressing the medical challenges, psychosocial needs, and access issues they may encounter.
Mantle Cell Lymphoma Consortium and Initiative
Recognizing that targeted research focuses on mantle cell lymphoma (MCL) would benefit this underserved and understudied patient population, LRF began awarding MCL-specific research grants and gathering its MCL grantees in the early 2000s for regular scientific meetings to report on their findings and form collaborations.
Oral Therapies in Lymphoma and Chronic Lymphocytic Leukemia Scientific Workshop Series
To raise awareness of the use of oral therapies in the treatment of lymphoma and chronic lymphocytic leukemia (CLL), LRF convened two national scientific workshops, seeking to better understand opportunities, challenges, and the role of these therapies play in the treatment of cancer.
Jaime Peykoff Follicular Lymphoma Initiative
Established in 2020 through the generosity of the Peykoff Family and Niagara Cares, the Initiative is poised to transform the follicular lymphoma treatment landscape for tens of thousands of patients by harnessing the Lymphoma Research Foundation’s (LRF) unique resources, convening the world’s experts in follicular lymphoma research and patient care, and driving direct investment in clinical research.
Marginal Zone Lymphoma International Scientific Workshop
LRF invested in the development of a global marginal zone lymphoma (MZL) Scientific Workshop that brought together the world’s leading MZL experts to discuss the latest research findings, foster collaboration within the MZL research community, and create a research agenda that would prioritize MZL research and improve MZL diagnosis and treatment.
Immunotherapy Response Criteria for Hematologic Malignancies Scientific Workshop
The Immunotherapy Response for Hematologic Malignancies Workshop, held in 2015 in partnership with the Cancer Research Institute, allowed leading clinicians and researchers to share their experiences with immunotherapy agents, then an emerging treatment for people with lymphoma.
Chronic Lymphocytic Leukemia Endpoints and Clinical Research Scientific Workshop
In the early 2000s, the research community witnessed a proliferation of experimental therapies for chronic lymphocytic leukemia (CLL). LRF convened a scientific workshop that provided a forum for experts in the field of CLL research to build consensus on the question, “What is a clinically meaningful response?” as it relates to new agents in development.
COVID-19 and Lymphoma Initiative
Since the beginning of the COVID-19 pandemic, LRF has sought to understand and address the unique challenges faced by people with lymphoma and CLL. By convening a panel of experts in the fields of lymphoma, epidemiology, infectious disease and public health, the Foundation has contributed to the body of evidence on this important subject and brought important attention to the needs of the lymphoma community.
Transformed Lymphomas and CLL Scientific Workshop
The Transformed Lymphomas and CLL Workshop marked the first time an international audience was convened to discuss the topic of transformation, when chronic lymphocytic leukemia (CLL) or an indolent non-Hodgkin lymphoma become aggressive lymphomas, both clinically and morphologically. The experts in attendance created a research roadmap and plan to address this important area of unmet need.
